Compare Blackrock Inc (BLK) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackrock Inc vs Quest Diagnostics Inc — how do they compare? Blackrock Inc trades at $1,154.12 (market cap $177.92B), while Quest Diagnostics Inc trades at $237.24 (market cap $26.21B). The key difference: Blackrock Inc is far larger — about 6.8× Quest Diagnostics Inc's market cap, and Blackrock Inc pays the higher dividend (2%). Which is the better fit depends on your goals.
| BLK | DGX | |
|---|---|---|
Market Cap | $177.92B | $26.21B |
Volume | 641,547 | — |
Sector | Financials | Health |
52-Week High | $1.20K | $238.50 |
52-Week Low | $922.90 | $173.49 |
Enterprise Value | $179.02B | $31.97B |
Dividend Yield | 2% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BlackRock (BLK) trades at $1,153.57, up 1.96% today, reflecting strong momentum. The stock shows bullish technical signals with consistent earnings beats in recent quarters, including Q2 2026 EPS of $13.91 versus $12.69 expected. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights BlackRock's involvement in a $500 billion AI financing initiative with partners like Apollo and Nvidia, signaling strategic growth avenues.
The outlook remains positive with a consensus price target of $1,350, implying 17% upside. Key opportunities include robust analyst support (79% buy ratings) and dividend stability, while risks involve legal investigations into mutual fund practices and volatile cash flows, with net cash flow negative $1.29 billion in 2025. Investors should weigh solid fundamentals against regulatory and execution risks.
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
